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Radiation therapy is considered effective in nasopharyngeal
carcinoma (NPC) and other head and neck malignancies.
However, it is not without morbidity, and complications
can develop as a result of damage to neighboring structures.
The irradiation field of head and neck neoplasms may
include brain tissue, which may result in brain radiation
necrosis. Reported cases of cerebral radionecrosis are still
rare in Taiwan. We present seven cases that were clinically
diagnosed as cerebral radionecrosis among NPC patients in
our institute. We also review cases of extracranial
malignancies, diagnostic modalities and treatment from
the literature.
CEREBRAL RADIONECROSIS IN PATIENTS WITH
NASOPHARYNGEAL CARCINOMA
Ying-Che Hsu, Ling-Feng Wang, Ka-Wo Lee, Kuen-Yao Ho, Chih-Jen Huang,1 and Wen-Rei Kuo
Departments of Otolaryngology and 1Radiation Oncology, Kaohsiung Medical University
Chun-Ho Memorial Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
This study involved seven patients with cerebral radionecrosis following radiation therapy for nasopharyngeal
carcinoma (NPC). Their charts were reviewed and the relationship of extracranial malignancies to cerebral
radionecrosis was investigated. The radiation dose ranged from 70 to 135 Gy, and the latency was from 6 to
39 months. Two of seven patients died of NPC-related complications during follow-up. The crude incidence
of cerebral radionecrosis in patients with NPC was 0.93% in our series. Improvement of symptoms could be
achieved by corticosteroid therapy, with or without surgery. In a review of the literature, there were 306 cases
of cerebral radionecrosis in extracranial malignancies. The nasopharynx is the most common primary site
in cerebral radionecrosis of extracranial malignancies, followed by the scalp and sinonasal tract. The 3-year
overall survival rate in our series was 68.57%, as provided by the Kaplan-Meier product limited method.
Cerebral radionecrosis in NPC patients should be differentiated from tumor recurrence, in order to apply
the appropriate treatment.
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MATERIALS AND METHODS
From 1991 to 2001, 775 patients with newly diagnosed
NPC received complete radiotherapy at Kaohsiung
Medical University Hospital. By May 2004, seven patients
had a clinical diagnosis of cerebral radionecrosis. Their
charts were retrospectively reviewed. There were four
male and three female patients. The mean age at diagnosis
of cerebral radionecrosis was 52.7 years (range, 34–74
years).
Four of seven patients had received neoadjuvant or
adjuvant chemotherapy with a cisplatin-based regimen
(cisplatin, 5-fluorouracil, and leucovorin). None had
concurrent chemoradiotherapy. One patient had diabetes
mellitus. Five patients with documented recurrence had
been re-irradiated. All patients were treated with 6 MV
photons using the same technique of two lateral-opposed
fields, supplemented by an anterior field. The radiation
dose per course was 65–70 Gy, delivered in 2-Gy fractions
© 2005 Elsevier. All rights reserved.
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via the lateral portal once daily for 5 days per week,
and 1.5-Gy (6 patients) or 1.8-Gy (1 patient) fractions 10
times via the anterior portal. The total radiation dose
ranged from 70 to 135 Gy (mean, 111 Gy), and the mean
latent period from the end of the last radiation to the
diagnosis of cerebral radionecrosis was 26.3 months
(range, 6–39 months).
Computed tomography (CT) or magnetic resonance
imaging (MRI) of the brain was performed in all patients.
The diagnosis of cerebral radionecrosis was confirmed by
surgical intervention in two cases and clinically diagnosed
based on CT or MRI in five cases. Five patients had a further
MRI perfusion-diffusion weighted scan. One had a Tc99m-
hexamethyl-propyleneamine oxime (HMPAO) single
photon emission CT (SPECT) scan of the brain.
A search of the English-language literature was
undertaken in PubMed (http://www.ncbi.nlm.nih.gov/).
RESULTS
The incidence of cerebral radionecrosis in NPC in this
series was 0.93% (7/755). Clinical symptoms and signs
included epilepsy, change in consciousness, memory
impairment, vertigo/dizziness, and headache (Table 1A
and 1B). Epilepsy was the main presenting symptom for
Patient 5, while Patient 4 only had vague symptoms and
developed epilepsy 19 months after the diagnosis of
cerebral radionecrosis by CT scan. Two patients (2 and 7)
had consciousness change as the initial manifestation.
Patient 3 had severe vertigo that made her normal daily
activity impossible. Patients 1 and 6 complained of
headache as their main symptom. Six of the seven patients
had an associated optic neuropathy.
Cerebral radionecrosis was mainly in the temporal
lobe of the brain. In five patients, diffusion-perfusion
weighted MRI of the intracranial lesion showed a high
signal in the diffusion-weighted image, and a low signal in
the perfusion-weighted image. Patients 1 and 2 had initial
surgical treatment with surgicopathologic documentation,
while the other patients were treated conservatively.
Patient 7 received betamethasone (0.75 mg/day), Patients
1, 3, 5, and 6 were given prednisolone (15 mg/day), and
Patient 2 was treated with cortisone (25 mg/day).
Patient 1 formed a brain abscess 20 months after the
diagnosis of cerebral radionecrosis and underwent
craniotomy. Patient 3 developed intracranial hemorrhage
17 months after diagnosis and presented with epilepsy.
The follow-up period lasted for a mean of 21.3 months
(range, 4–36 months). Six patients had a favorable response
to corticosteroids, with or without surgery, while one
(Patient 4) was treated only with an anti-epileptic agent.
Two patients eventually died of NPC-related complications
during follow-up.
Table 1A. Patient data
Patient Sex Age at TNM Tumor Total C/T Latency Lesion site
diagnosis of recurrence dose (Mo)
radionecrosis (Yr) (Gy)
1 M 34 T4N0M0 Yes 135.0 2 course adj 18 Bil T
2 M 60 T4N1M0 Yes 131.5 6 course adj 14 LT R cerebral
3 F 58 T2N2M0 No 72.5 N 38 Bil T
4 M 45 T3N2M0 Yes 121.0 N 38 Bil T
5 M 50 T4N0M0 Yes 126.0 2 course neoadj 6 Bil T LF
6 F 52 T4N0M0 No 70.0 9 course adj 31 RT
7 F 74 T2N1M0 Yes 121.0 N 39 Bil T
C/T = chemotherapy; adj = adjuvant chemotherapy; Bil T = bilateral temporal; neoadj = neoadjuvant chemotherapy; LF = left frontal;
RT = right temporal; TNM = tumor-node-metastasis staging.
Chemotherapy regimen: cisplatin-based.
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DISCUSSION
The incidence of NPC is higher in Southeast Asia than in the
West. Radiation therapy is the main treatment modality, and
the irradiation field inevitably covers the medial and inferior
temporal lobes of the brain, owing to the close proximity to
the skull base. In addition, the radiation dose is usually
65–70 Gy, which exceeds the tolerance of brain tissue.
Radionecrosis is a late complication of radiotherapy.
The first case of extracranial neoplasm with cerebral
radionecrosis was described by Fischer and Holfelder in
1930 [1]. In 1984, Glass et al reported nine cases of cerebral
radionecrosis and reviewed another 65 cases in the literature
[2]. Since then, another 232 patients have been reported,
including our series (Table 2) [2–31], giving a total of 306
cases of cerebral radionecrosis in extracranial malignancy.
The most common primary site of malignancy is the
nasopharynx (mainly NPC), followed by the scalp and the
sinonasal tract.
In our institute, cerebral radionecrosis was detected in
seven cases, giving a crude incidence of 0.93%. The reported
incidence of radionecrosis in NPC patients ranges from
0.40% to 18.60% with different radiation regimens [3,32,33].
Lee et al reported that 64 Gy at the conventional fraction of
2 Gy daily would lead to a 5% necrotic rate in 10 years [32].
Hence, the incidence of radionecrosis in NPC in our patients
is thought to be underestimated. This may be because the
fractional dose via the anterior portal was low (1.5 or 1.8 Gy)
compared to the normal fractional dose (1.8–2.0 Gy). Other
anatomic sites reported in the literature are summarized in
Table 2.
The period between the last irradiation and the diagnosis
of cerebral radionecrosis in our series ranged from 6 to 39
months (mean, 26.3 months). Latency has been reported at
1 month to 16 years after the end of irradiation [34], with
approximately 80% occurring within 3 years after the last
dose of radiotherapy [2]. The mechanism is thought to be
endothelial cell damage, resulting in brain tissue ischemia
in long-term follow-up [35,36].
The radiation dose in our series ranged from 70 to 135
Gy (mean, 111 Gy). The average dose was higher in our
series because five of our seven cases had documented
recurrent disease. A dose of 60 Gy delivered in 1.8–2-Gy
fractions represents the upper limit of the “safe dose” to
brain tissue [37]. To treat NPC, the radiation dose inevitably
exceeds this limit. The irradiation field used to treat NPC
and other malignancies of the sinonasal tract and scalp may
include a part of the brain tissue. The ratio of brain tissue
irradiated may be higher for scalp tumors than those in the
nasopharynx, which makes the scalp the second most
frequent tumor site associated with cerebral radionecrosis.
The threshold for injury may be lowered by hypertension
[38] or concomitant chemotherapy [39,40], although the
effect of induction or adjuvant chemotherapy has not been
reported. Old age or systemic illness may play a role in
developing radionecrosis. Lee et al analyzed their irradiation
regimen and concluded that the most significant factor was
the fractional dose [32]. Prolonging the treatment time
offered little protective effect [32], and yet, the overall
treatment time had a significant impact [41]. The age at the
time of radiotherapy also appeared to affect the volume of
radionecrosis [42].
The clinical symptoms of cerebral radionecrosis are
variable. It may manifest major symptoms, such as changes
in consciousness and seizures, or minor complaints, such as
dizziness, vertigo or memory impairment. In our series,
consciousness change was detected in two cases, headache
in two, epilepsy in one and vertigo in one. One patient had
vague symptoms. If a patient has neurologic or psychiatric
symptoms, an encephalopathy must be ruled out [4]. Patients
with temporal lobe radionecrosis have significant
impairments in memory, language, motor ability, and
executive function, compared with those without
radionecrosis [5]. Asymptomatic patients are sometimes
found by follow-up imaging studies.
Distinguishing radionecrosis from tumor is a challenge
in traditional imaging studies. The general characteristics
of cerebral radionecrosis and tumors are summarized in
Table 3. Differentiating radionecrosis from recurrent tumor
is difficult with CT or MRI findings alone because of similar
Table 2. Primary malignancy site of cerebral radionecrosis in
extracranial malignancy
Location n
Nasopharynx
In the literature [2–17] 220
This series 7
Total 227
Scalp [2,18–22] 32
Sinonasal tract [2,17,23–28] 23
Ear [2,17] 9
Oropharynx [2] 2
Lacrimal gland [2] 4
Submandibular gland [2] 1
Parotid gland [2,29,30] 5
Glomus jugulare tumor [2] 1
Orbit [2,31] 2
Total 306
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imaging characteristics. Scintigraphic studies, such as
18F-fluorodeoxyglucose positron emission tomography or
201Tl chloride SPECT, have been reported to sensitively
distinguish recurrent tumor from radionecrosis [43]. Recent
MRI techniques, such as perfusion- and diffusion-weighted
scans or MR spectroscopy to detect the brain N-
acetylaspartate/choline ratio, may also help distinguish
the lesion [7,8,44]. However, pitfalls in scintigraphic imaging
have also been reported [18,23,24].
The standard diagnosis of radiation necrosis is histologic
verification, and two of our seven patients had initial surgical
treatment. The pathologic features of radionecrosis were
fibrinoid and coagulation necrosis of the brain tissue. Even
though surgery is an invasive procedure, it should be
undertaken if the diagnosis is unclear. The surgical
exploration rate may be reduced and the diagnostic rate
may be increased by combining imaging studies and clinical
characteristics. The clinical diagnosis of cerebral
radionecrosis without pathologic proof in NPC patients has
been discussed [6], and one study reported direct biopsy
under local anesthesia via a left temporal craniotomy by the
neurosurgeon [30].
Treatment includes conservative management with
corticosteroid or invasive procedures, such as craniotomy
to clean necrotic tissue or brain lobectomy [9]. Six of our
seven cases showed clinical improvement after
corticosteroid therapy, with or without surgical treatment.
The reported regimen is dexamethasone 4–16 mg/day for
4–6 weeks, which is gradually tapered off [3,10]. Tsui et al
point out that a perfusion and diffusion mismatch might
imply injured tissue, such as edema and potentially
salvageable brain tissue, and this may be used to predict
response to treatment [8]. Lee et al reported a mortality rate
of 8% due to uncontrolled sepsis, with a 44% associated
side-effect rate in corticosteroid treatment [3]. Hyperbaric
oxygen therapy has also been reported [45].
Patient 3 developed a brain abscess 17 months after the
diagnosis of cerebral radionecrosis. She underwent
craniotomy and her symptoms improved, which stabilized
her condition for the following 5 months of follow-up.
Table 3. Diagnostic tools and general characteristics of recurrent nasopharyngeal carcinoma and cerebral radionecrosis
Diagnostic tool Recurrent nasopharyngeal Cerebral radionecrosis Note
carcinoma
Angiography Avascular space-occupying lesion
CT [4] Low-density, Digitiform or round hypodense lesion Reported detection rate: 50%
post-contrast enhancement Post-contrast enhancement Detection rate < MRI
PET-18 FDG B uptake ? uptake Expensive and limited availability
SPECT B uptake ? uptake No significant differences in
sensitivity or specificity for
FDG-PET and 201Tl SPECT
MRI [6] Low signal in T1W, Low signal in T1W, Poorly differentiated from
high signal in T2W High signal in T2W tumor with only T1W, T2W
Heterogeneous contrast Heterogeneous contrast Superior sensitivity to
enhancement enhancement CT scan
Irregular or cystic shape Lesions best shown on T2W
MRI perfusion-weighted High signal Low signal
scan (rrCBV map)
MRI diffusion-weighted Low signal High signal
scan (ADC map) [7]
MR spectroscopy [44] B NAA/Cr ratio B Choline peak and ? NAA/Cr ratio
CT = computed tomography; MRI = magnetic resonance imaging; PET-18 FDG = 18F-fluorodeoxyglucose positron emission tomography;
SPECT = single photon emission computed tomography; T1W = T1 weighted; T2W = T2 weighted; rrCBV = relative regional blood volume;
ADC = apparent diffusion coefficient; NAA/Cr = N-acetylaspartate/choline ratio.
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Cheng et al reported six cases complicated by brain abscess
formation in 28 patients with temporal lobe radionecrosis
following radiotherapy for NPC [46]. Cerebral radiation
necrosis is a predisposing cause of brain abscess formation,
as is the use of corticosteroids. Surgical excision is the
recommended treatment.
Six of our patients had optic neuropathy, possibly
because of the higher radiation dose due to tumor recurrence.
One patient with a lower irradiation dose had diabetes
mellitus (Patient 3), which may exacerbate the impairment
of microcirculation caused by radiotherapy. The patient
developed intracranial hemorrhage 17 months after the
diagnosis of cerebral radionecrosis (55 months after the end
of radiotherapy). Cheng et al reported five cases of acute
hemorrhage in late radiation necrosis of the temporal lobe
[47]. The interval between the onset of hemorrhage and
cranial irradiation was long (mean, 7.8 years), and rupture
of the thin-walled new blood vessel is the hypothesized
hemorrhage mechanism.
Clinical improvement has been reported in the treatment
of cerebral radionecrosis using anti-coagulation therapy
with heparin and warfarin [48]. Anti-platelet treatment
with pentoxyfyllin, aspirin, and ticlopidine has also been
used, but the potential risk of bleeding from these agents
must be considered [49].
The follow-up time after diagnosis of cerebral
radionecrosis ranged from 4 to 36 months (mean, 21.3
months). Two of our seven patients died. The 3-year overall
survival rate in our series was 68.57%, as provided by the
Kaplan-Meier product limited method. Lee et al found a
5-year survival rate for cerebral radionecrosis in NPC of
59%, with or without treatment [33]. The weak points of our
sampling were the relatively short follow-up time and the
limited numbers of cases.
CONCLUSIONS
Patients with NPC comprise the majority of those
with cerebral radionecrosis following treatment for
extracranial malignancies. Differential diagnosis with
tumor recurrence is needed. Since advances in the treatment
of NPC have resulted in an accumulation of long-term
survivors, cerebral radionecrosis may become a major
clinical concern. Several studies have shown that a
promising first-line treatment is with corticosteroids [3,4,
10,11]. The consequences of cerebral radionecrosis, which
include brain abscess and acute hemorrhage, are also of
chief concern.
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